Pseudohypoaldosteronism type 1 (PHA1) is a rare condition characterized by neonatal salt loss with dehydration, hypotension, hyperkalemia, and metabolic acidosis, despite elevated plasma aldosterone levels and PRA. Two modes of inheritance of PHA1 have been described: an autosomal dominant form and an autosomal recessive form. An autosomal recessive form manifests severe life-long salt wasting resulting from multiple mineralocorticoid target tissue such as sweat, salivary glands, the colonic epithelium, and lung. Contrary, an autosomal dominant PHA1 manifests milder salt wasting that gradually improves with advancing age. Recently, in one sporadic and four dominant cases, four different mutations including two frame shift mutations, two premature termination codons, and one splice site mutation in the mineralocorticoid receptor (MR) gene were identified.
We studied the molecular mechanisms of one Japanese family with a renal form of PHA1. PCR and direct sequencing of the MR gene identified a heterozygous point mutation changing codon 924 Leu (CTG) to CCG (Pro) (L924P) in all affected members. COS-1 cells were transfected with expression vectors for either wild type or the mutant MR-L924P receptors, together with the reporter plasmid (glucocorticoid response element tk-CAT). Aldosterone increased CAT activity in cells expressing wild-type receptor, but had no effect in cells expressing the mutant receptors. These results suggest that mineralocorticoid resistance in this family is due to a missense mutation in the MR gene. To our knowledge, this is the first case of the missense mutation of the MR gene in renal PHA1. (J Clin Endocrinol Metab 85: 4690 -4694, 2000) P SEUDOHYPOALDOSTERONISM type 1 (PHA1) is characterized by congenital resistance of the kidney and/or other mineralocorticoid target tissues to aldosterone, resulting in excessive salt wasting. Two modes of inheritance of PHA1 have been described: an autosomal dominant form and an autosomal recessive form. An autosomal recessive form manifests severe life-long salt wasting resulting from multiple mineralocorticoid target tissue such as sweat, salivary glands, the colonic epithelium, and lung (1) (2) (3) (4) (5) (6) . On the other hand, an autosomal dominant PHA1 manifests milder salt wasting that gradually improves with advancing age (3, 7, 8) . In autosomal dominant form the target organ defect is confined to renal tubules only.
The loss of function mutations of the amiloride-sensitive epithelial sodium channel were identified in the autosomal recessive familial PHA1 (6, 9, 10) . On the other hand, a recent report has identified the nonsense and frameshift mutations of the mineralocorticoid receptor (MR) gene in several patients with a renal form of PHA1 ( Fig. 1) (8) . These findings indicate that at least some cases of renal PHA1 are a disease of the mineralocorticoid resistance due to the dysfunction of the MR (8) . MRs belonging to the steroid hormone receptor family are conditional transcriptional factors that play important roles by controlling specific genes (11) (12) (13) (14) . Members of the steroid hormone receptor family are structurally characterized by three distinct domains: an N-terminal transcriptional activation domain, a central DNA binding domain (DBD), and C-terminal ligand-binding domain (LBD). This LBD exerts multifunctional actions such as dimerization and ligand-dependent transactivation function (11) (12) (13) (14) .
To elucidate the molecular basis of one Japanese family with a renal form of PHA1, we analyzed the mutation and functioning of MR. A novel missense mutation in exon 8 of LBD in the MR gene was identified. In vitro study demonstrated that this mutant MR could not enhance the aldosterone-dependent transactivation activity.
Subjects and Methods Subjects
Pedigree and endocrine findings in the family are shown in Fig. 2A and Table 1 . The proband (II-1) was born by spontaneous vaginal delivery at full term. There was no consanguinity. At 2 weeks of age she presented with poor weight gain and failure to thrive. Initial laboratory examinations showed hyponatremia (129 mmol/L), hyperkalemia (6.8 mmol/L), an extremely elevated plasma aldosterone concentration (24,880.2 pmol/L), and PRA (Ͼ25 g/L/h) ( Table 1) . Urinary Na and K levels were 41 mmol/L and 21 mmol/L, respectively, and a urinary Na value was inappropriately high in the face of hyponatremia (Table  1 ). Adrenal and renal functions were normal. The electrolyte disturbance quickly resolved with salt supplementation (1 g/day), and weight gain was restored to normal. At 10 months of age salt supplement was withheld, and she remains well and is growing normally since then. Her mother (I-2) demonstrated elevated plasma aldosterone concentration (1,658.8 pmol/L) ( Table 1) , and she reported the episode of poor weight gain until 8 months of age. The younger brother of the proband (II-2) was also hospitalized for poor weight gain and failure to thrive at the age of 7 days. His serum sodium was 132 mmol/L; potassium, 4.9 mmol/L; plasma aldosterone, 15,040.6 pmol/L; and PRA, Ͼ25 g/L/h ( Table 2) . Urinary Na and K levels were 36 mmol/L and 29 mmol/L, respectively. Salivary Na and Cl were 13 mmol/L and 9 mmol/L, respectively, within normal range (Table 1) . He was also treated with salt supplementation (1 g/day). Serum sodium returned to normal values, and he has gradually improved over time with diminishing needs for salt supplementation. Sodium supplementation was discontinued at age 11 months.
Based on these findings and family history, the proband, her younger brother, and her mother were diagnosed as having a renal form of PHA1.
Methods
This study was approved by the internal review board, and informed consent for DNA analysis was obtained from their parents.
MR gene analysis
To analyze the MR gene from this family, DNA was prepared from white blood cells using standard techniques. The primers of PCR were selected in the intron-exon boundaries of the MR gene according to published sequences of the MR gene (8) . All PCR was conducted with primer pairs, consisting of 5 min 94 C, followed by 30 cycles of 40 s at 94 C, 40 s at 57 C, and 1 min at 72 C. If nonspecific bands were present, the expected PCR product was purified by 2% NuSieve (FMC Bioproducts, Rockland, ME) gel electrophoresis. Direct sequence of these PCR products was performed using the ABI PRISM Dye Terminator Cycle Sequencing Kit and automated fluorescent sequencer ABI 373A (PE Applied Biosystems, Foster City, CA), according to a previous method (15) .
Ligand-induced receptor function of wild type and the mutant MR
The technique of site-directed mutagenesis by overextension PCR was used to replace the cytosine (C) residue at position of the normal human MR cDNA with a thymidine (T) residue, using the MR cDNA. The recombinant plasmid was designated MR-L924P. COS-1 cells were cultured, and cotransfections with 1 g of either the wild-type MR or the mutant MR-L924P and 3 g reporter plasmid of glucocorticoid response element (GRE)-tk-CAT, reporter plasmid, in which GREs are coupled to the CAT gene, were carried out in the presence of lipofectin reagent (Life Technologies, Gaithersburg, MD) (16) . Cells were incubated with 10 nm aldosterone. CAT assay was performed as described previously (16) .
Results

MR gene analysis
Sequencing of exon 8 of the MR gene in the proband (I-1) revealed the heterozygous point mutation changing codon 924 Leu (CTG) to CCG (Pro) (L924P) (Fig. 2B) . Her younger brother (II-2) shared this heterozygous mutation (Fig. 2C) . Although their father (I-1) did not have any mutation of the MR gene (Fig. 2D) , their mother (I-2) had also both of the normal and mutant alleles (Fig. 2E) . To determine whether this mutation was not merely polymorphism, we sequenced the MR gene from 50 normal Japanese individuals by PCRdirect sequencing, and none had this nucleotide transition. These results strongly indicate that this mutation is responsible for the development of this disorder, and that the inheritance might be autosomal dominant.
Functional analysis
After transfection, we determined mRNA levels by Northern blot analysis, and there was no difference in the wild and mutant receptor (data not shown). To determine whether the identified base substitution is responsible for mineralocorticoid resistance, COS-1 cells were transfected with the wild-type or the mutant MR-L924P plasmid, together with GRE-tk-CAT. In cells transfected with the wild-type MR, aldosterone induced a 7-fold increase in CAT activity (Fig. 3) . However, there was no stimulation of CAT activity by aldosterone in cells, which had been transfected with the mutant MR-L924P plasmid (Fig. 3) , indicating that this mutant receptor can not transduce liganddependent transactivation.
Discussion
We have identified a novel missense mutation (L924P) in the MR gene in a Japanese family with a renal form of PHA1. So far, four mutations of the MR gene were identified in either autosomal dominant or one sporadic case of a renal form of PHA1. These mutations included the stop codon mutation in exon 2, two frameshift mutations by one base deletion, leading to a premature stop codon, and a single base pair deletion, resulting in aberrant splicing ( Fig. 1 and Table  2 ) (8). Our study detected the first case of the amino acid substituting mutation on the MR gene. This Leu at position 924 lies in the LBD of the MR, and is conserved in all members of the steroid hormone receptor family (11) (12) (13) (14) 16) . Moreover, segregation of the allele bearing this mutation is consistent with the disease manifestation in this family. These findings strongly suggest that the identified point mutation is not a nonfunctional polymorphism. The in vitro expression studies provided definitive confirmation for this, because the L924P has the impaired ability to activate gene expression through hormone response elements in the presence of aldosterone. The exact molecular mechanism has yet to be determined, however, a previous study revealed that this Leu residue was critical for dimerization (14) . In this study, the mutant mouse estrogen receptor of substituting the Leu at codon 511 with Arg, which corresponds with Leu at codon 924 of the MR, was not able to dimerize efficiently and bind DNA, although this mutant retained the ability of the hormone binding (14) . Because the binding of hormone induces critical conformation changes in steroid hormone receptors, the dimerization of receptors, and subsequently steroid hormone receptors can interact with required transcriptional coactivators and target genes (11) (12) (13) (14) 16) , the interruption of dimerization would impair the normal function of steroid receptor. Thus, our mutant receptor (MR-L924P) might be the cause of MR resistance.
As stated above, there are only five cases (case 1, 2-1, 3-1, 4-1, and 5-1) of renal PHA1, in whom MR mutations were identified ( Table 2 ). All these patients showed renal salt wasting with hyperkalaemic acidosis despite high aldosterone levels, and improved with age and were asymptomatic without treatment (8) . MR mutations of these patients would lead to a truncated protein, thus resulting in a complete loss of MR function (Table 2) (8). Our missense mutation, L924P, affects a highly conserved residue and results in complete (II-1) . The T residue was changed to C residue, accompanying with the substitution of Pro (CCG) for Leu (CTG) at codon 924 in exon 8 denoted by an arrowhead. The determination of whole sequence confirmed the mutation was on only one allele. C, His brother (II-2) shared the same mutation as heterozygous. D, While their father (I-1) had only wild-type alleles, their mother (II-2) (E), with a renal form of PHA1, had the wild and mutant alleles.
absence of MR function. Thus, all mutations of MR have equally severe functional consequences in vitro. Accordingly, this severe heterozygous loss of function mutations would develop clinically evident disease. However, regarding with serum Na, K, and plasma aldosterone in patients and affected family members, their ranges are variable despite of severe mutations of the MR gene (Table 2) . It is also reported that many adult gene carriers have elevated aldosterone concentrations but no history of clinical manifestations (8) . Moreover, several dominant and many sporadic kindreds do not have MR gene mutation (8) . Taken together, it is possible that not only MR mutation, but also either mutations in additional genes or nongenetic factor may contribute to clinical and biochemical phenotypes. To address these issues, it is necessary to analyze more patients with a renal form of PHA1.
In conclusion, we identified a novel missense mutation of the MR gene in a Japanese family with a renal form of PHA1. To our knowledge, this is the first report that the naturally occurring mutant MR can not activate ligand-dependent transactivation. This will give new insights for understandings the pathophysiology of this disorder. 
